Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 1.00 |
| ▸ | TLR9 | Q9NR96 | 11/20 | 1.00 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.36 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.36 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.36 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HCK | P08631 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18788766 | 0.89 | TLR8 (0.80) | TLR8TLR9TLR7KCNH2PIK3CA | |
| SCHEMBL4228277 | 0.83 | TLR7 (0.70) | TLR8TLR9TLR7PIK3CAMTOR | |
| SCHEMBL4215022 | 0.81 | TLR7 (0.74) | TLR8TLR9TLR7PIK3CAMTOR | |
| SCHEMBL4214625 | 0.81 | TLR7 (0.74) | TLR8TLR9TLR7PIK3CAMTOR | |
| SCHEMBL4047282 | 0.81 | TLR7 (0.67) | TLR8TLR9TLR7PIK3CAMTOR | |
| SCHEMBL4044815 | 0.80 | TLR7 (0.72) | TLR8TLR9TLR7PIK3CAMTOR | |
| SCHEMBL4046635 | 0.80 | TLR7 (0.67) | TLR8TLR9TLR7PIK3CAMTOR | |
| SCHEMBL4275196 | 0.79 | TLR7 (0.74) | TLR8TLR9TLR7PIK3CAMTOR | |
| SCHEMBL4226497 | 0.79 | TLR7 (0.79) | TLR8TLR9TLR7BTKTNK2 | |
| SCHEMBL4234554 | 0.79 | TLR7 (0.65) | TLR8TLR9TLR7PIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| EP-3873532-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3797797-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| EP-3368092-B9 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-20200164084-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2020-05-28 | — | — | US | disclosed |
| EP-3368092-B1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| EP-3615033-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018198091-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
| EP-3368092-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | Novartis AG (CH) | 2018-09-05 | — | — | EP | disclosed |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| WO-2017072662-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | TLR8 9/4885TLR9 3/4885TLR7 6/4885 |
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | DCUN1D4, CD14, DCUN1D3 | TLR8 390/4885TLR9 127/4885TLR7 249/4885 |
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | TLR8 9/4885TLR9 3/4885TLR7 6/4885 |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | TLR3, TLR2, TLR9 | TLR8 9/4885TLR9 3/4885TLR7 6/4885 |
| US-20200164084-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | TLR3, TLR2, TLR9 | TLR8 7/4885TLR9 3/4885TLR7 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.